|
Match
|
Document |
Document Title |
|
|
US20140205621 |
CANINE CORONAVIRUS VACCINE
A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described. |
|
|
US20140294879 |
MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as... |
|
|
US20150093404 |
PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF
Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2... |
|
|
US20120282217 |
FOOT AND MOUTH DISEASE VIRUS (FMDV) CONSENSUS PROTEINS, CODING SEQUENCES THEREFOR AND VACCINES MADE THEREFROM
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as... |
|
|
US20130028925 |
HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF
This invention provides immunogenic compositions comprising two or three recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of... |
|
|
US20120177675 |
Chimaeric Protein
The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the... |
|
|
US20140205620 |
ENGINEERED RESPIRATORY SYNCYTIAL VIRUSES WITH CONTROL OF CELL-TO-CELL VIRUS TRANSMISSION FOR ENHANCED SAFETY OF LIVE VIRUS VACCINES
Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae... |
|
|
US20140335116 |
AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES
The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines. |
|
|
US20150147329 |
INFLUENZA TREATMENT AND/OR CHARACTERIZATION, HUMAN-ADAPTED HA POLYPEPTIDES; VACCINES
The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections. |
|
|
US20110123560 |
Infectious Bursal Disease Virus Antigenic Isolates And Vaccines
Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate. |
|
|
US20140314858 |
IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLE-BASED PLATFORM AND METHODS OF USING THE SAME
The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (IPNV) and infectious salmon anemia virus (ISAV). Yeast cells comprise an expression vector... |
|
|
US20140127247 |
VACCINES FOR HSV-2
Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural... |
|
|
US20140086947 |
VACCINES FOR HSV-2
Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural... |
|
|
US20130315916 |
RESPIRATORY SYNCYTIAL VIRUS VACCINE
Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH)... |
|
|
US20130089596 |
COMPOSITIONS AND METHODS OF MAKING AND USING INFLUENZA PROTEINS
The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune... |
|
|
US20130209499 |
VACCINES FOR USE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA VIRUS DISEASE
Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their... |
|
|
US20140147460 |
TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 33
The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising... |
|
|
US20130122032 |
RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as... |
|
|
US20140072591 |
IPN VACCINE
The present invention relates to a live avirulent infectious pancreatic necrosis virus which has been shown to be genetically stable in biological studies. Fish exposed to said virus turn out... |
|
|
US20130115234 |
Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment... |
|
|
US20120141520 |
RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS
A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is... |
|
|
US20150125384 |
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric... |
|
|
US20120045469 |
VACCINE
The present invention provides an immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising an... |
|
|
US20140220061 |
YEAST EXPRESSION OF FLAVIVIRUS VIRUS-LIKE PARTICLES AND USE THEREOF
Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a Pichia pastoris strain... |
|
|
US20140199337 |
INFLUENZA H5 VACCINES
The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza... |
|
|
US20130071419 |
UNIVERSAL DENGUE VIRUS SEQUENCES AND METHODS OF USE
Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments... |
|
|
US20140037665 |
PESTIVIRUS SPECIES
The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further... |
|
|
US20120237519 |
PESTVIRUS SPECIES
The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further... |
|
|
US20140105925 |
Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection
Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate... |
|
|
US20120045467 |
INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one... |
|
|
US20150104475 |
COMPOSITIONS AND METHODS RELATED TO VIRAL VACCINES
Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof. |
|
|
US20130259869 |
REARRANGED TT VIRUS MOLECULES FOR USE IN DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER AND AUTOIMMUNITY
The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated... |
|
|
US20130295124 |
ORF7 DEFICIENT VARICELLA VIRUS, VACCINE COMPRISING THE VIRUS AND USE THEREOF
Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus. |
|
|
US20140356388 |
Vaccine - Screening Method
The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded... |
|
|
US20150196631 |
VACCINE COMPOSITIONS
The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease. |
|
|
US20150079122 |
HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS
A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof,... |
|
|
US20120121629 |
NEW HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS
A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof,... |
|
|
US20140193446 |
BIODEGRADABLE HIGH-EFFICIENCY DENGUE VACCINE, METHOD FOR MAKING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
The present invention is related to a biodegradable high-efficiency dengue vaccine, a method for making the same, and a pharmaceutical composition comprising the same. The biodegradable... |
|
|
US20130230548 |
TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 52
Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a... |
|
|
US20130259886 |
BROADLY PROTECTIVE INFLUENZA T-CELL VACCINE AGAINST DIVERSE INFLUENZA A VIRUSES
There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for... |
|
|
US20140220062 |
CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV
The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the... |
|
|
US20120100169 |
Vaccine for Cervical Cancer
The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1... |
|
|
US20130230549 |
FOOT AND MOUTH DISEASE VIRUS WITH INCREASED STABILITY AND ITS USE AS VACCINE
The present invention provides a foot and mouth disease (FMD) virus having improved stability compared to the field isolate of the same subtype, wherein the virus comprises one or more amino acid... |
|
|
US20130315943 |
TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 58
Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the... |
|
|
US20140147458 |
NOVEL VARICELLA-ZOSTER VIRUS STRAINS, AND CHICKEN POX AND HERPES ZOSTER VIRUS VACCINE USING SAME
The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome... |
|
|
US20110014220 |
HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE
The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a... |
|
|
US20140249467 |
CROSS-PROTECTIVE ARENAVIRUS VACCINES AND THEIR METHOD OF USE
The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously. |
|
|
US20140234358 |
NEWCASTLE DISEASE VIRUS VECTORED AVIAN VACCINES
The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses... |
|
|
US20150157704 |
Newcastle Disease Virus Vectored Herpesvirus Vaccines
The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus... |
|
|
US20130101612 |
VACCINE FOR ENVELOPED VIRUSES
The present invention provides a recombinant viral surface antigenic protein with enhanced stability. The present invention also provides a vaccine composition against enveloped viruses. |